[HTML][HTML] NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer …
L Fehrenbacher, RS Cecchini, CE Geyer Jr… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
L Fehrenbacher, RS Cecchini, CE Geyer Jr, P Rastogi, JP Costantino, JN Atkins, JP Crown…
Journal of Clinical Oncology, 2020•ncbi.nlm.nih.govPURPOSE Adjuvant trastuzumab reduces invasive breast cancer (IBC) recurrence and risk
for death in patients with HER2-amplified or overexpressing IBC. A subset of patients in the
landmark trastuzumab adjuvant trials who originally tested HER2-positive but were HER2-
negative by central HER2 testing appeared to possibly benefit from trastuzumab. The
objective for the NSABP B-47 trial was to determine whether the addition of trastuzumab to
adjuvant chemotherapy (CRx) would improve invasive disease-free survival (IDFS) in …
for death in patients with HER2-amplified or overexpressing IBC. A subset of patients in the
landmark trastuzumab adjuvant trials who originally tested HER2-positive but were HER2-
negative by central HER2 testing appeared to possibly benefit from trastuzumab. The
objective for the NSABP B-47 trial was to determine whether the addition of trastuzumab to
adjuvant chemotherapy (CRx) would improve invasive disease-free survival (IDFS) in …
Abstract
PURPOSE
Adjuvant trastuzumab reduces invasive breast cancer (IBC) recurrence and risk for death in patients with HER2-amplified or overexpressing IBC. A subset of patients in the landmark trastuzumab adjuvant trials who originally tested HER2-positive but were HER2-negative by central HER2 testing appeared to possibly benefit from trastuzumab. The objective for the NSABP B-47 trial was to determine whether the addition of trastuzumab to adjuvant chemotherapy (CRx) would improve invasive disease-free survival (IDFS) in patients with HER2-negative breast cancer.
ncbi.nlm.nih.gov